{"entity":{"id":"ian-davis","kind":"person","name":"Ian Davis","aka":[],"tldr":"Melbourne medical oncologist who chairs ANZUP, the Australia and New Zealand urogenital and prostate cancer trials group.","summary":"Ian Davis is Chair of the ANZUP Cancer Trials Group and Head of the Eastern Health Clinical School at Monash University. He is a medical oncologist whose research focuses on prostate, kidney, bladder and testicular cancers, including practice-changing trials such as ENZAMET in metastatic prostate cancer. He has been a central figure in building Australasia's genitourinary cancer trials infrastructure.","asOf":"2026-09-10","links":[{"label":"Society page","url":"https://anzup.org.au/about-us/board/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Davis+ID%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","prostate cancer","genitourinary oncology"],"related":[],"cancers":["prostate","rcc","urothelial"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["anzup"],"institutions":[],"pathways":[],"terms":[],"trials":["propsma"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chair","institutionId":"anzup","specialisms":["Genitourinary oncology","Prostate cancer","Clinical trials"],"profiles":[{"label":"Society page","url":"https://anzup.org.au/about-us/board/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Davis+ID%5BAuthor%5D"}],"papers":[{"title":"Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer","journal":"New England Journal of Medicine","year":2019,"doi":"10.1056/nejmoa1903835"},{"title":"TheraP: a randomized phase 2 trial of 177 Lu‐ PSMA ‐617 theranostic treatment vs cabazitaxel in progressive metastatic castration‐resistant prostate cancer (Clinical Trial Protocol ANZUP 1603)","journal":"BJU International","year":2019,"doi":"10.1111/bju.14876"},{"title":"Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial","journal":"The Lancet Oncology","year":2020,"doi":"10.1016/s1470-2045(20)30456-3"}],"orcid":"0000-0002-9066-8244"},"route":"/people/ian-davis/","neighbours":{"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"},{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/"}],"company":[{"id":"anzup","kind":"company","name":"ANZUP Cancer Trials Group","route":"/companies/anzup/"}],"trial":[{"id":"enzamet","kind":"trial","name":"ENZAMET","route":"/trials/enzamet/"},{"id":"propsma","kind":"trial","name":"proPSMA","route":"/trials/propsma/"}]}}